Organ Engineer Reinvestigated

Paolo Macchiarini will again be investigated by the Karolinska Institute, which is not extending the researcher’s employment contract.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

An artificial trachea, similar to those transplanted by Macchiarini, made by seeding an inorganic scaffold with stem cellsUCLOnce hailed as an artificial organ transplant pioneer, Paolo Macchiarini is again facing an investigation into his research practices. The probe is being initiated by his employer, the Karolinska Institute in Stockholm, Sweden. The institute’s University Board announced today (February 5) that it will launch an external investigation into Macchiarini’s work at Karolinska over his more than five years there. “The University Board deems such an inquiry to be an important part of restoring the confidence of the public, the scientific community, staff and students in the university,” according to the Karolinska statement. The institute also announced that it would not be renewing Macchiarini’s contract. He has served as a visiting professor at Karolinska since 2010.

There were hints that the Karolinska Institute would reopen its investigation of Macchiarini earlier this week, after a Swedish documentary series aired new information on his case. The thoracic surgeon had previously faced allegations—including an investigation launched by the Karolinska Institute—of misconduct related to his artificial trachea research.

Karolinska’s board also reaffirmed its support of vice chancellor Anders Hamsten, who had headed the institute’s previous investigation, which did not find conclusive evidence of scientific misconduct in Macchiarini’s case. “I intend to continue as vice-chancellor of Karolinska Institutet with full force and energy, and to execute my responsibility in this situation in the best possible way,” Hamsten told Retraction Watch. “The decisions taken by the board are fully in line with what I myself believe must ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies